论文部分内容阅读
目的:分析恩替卡韦对乙型肝炎相关原发性肝癌患者的预后情况。方法:选取2012年1月—2014年1月期间收治的乙型肝炎相关原发性肝癌患者86例作为研究对象,根据其入院治疗的先后顺序将其分为对照组和观察组,每组43例;对照组患者给予常规治疗方法治疗,观察组患者在对照组治疗基础上给予恩替卡韦抗病毒治疗,评价两组患者治疗后12周、24周的各项指标水平值的变化。结果:观察组患者治疗后12周、24周的各项指标水平含量均明显优于对照组(P<0.05);从HBe Ag转阴率方面比较,观察组患者治疗的转阴率为32.56%显著高于对照组为9.30%(P<0.05)。结论:恩替卡韦用于治疗乙型肝炎相关性肝癌患者能够有效提升其治疗预后效果。
Objective: To analyze the prognosis of patients with hepatitis B-related primary liver cancer treated with entecavir. Methods: Totally 86 patients with primary hepatocellular carcinoma (HCC) treated during January 2012 to January 2014 were enrolled in this study. They were divided into control group and observation group according to the sequence of admission and treatment Patients in the control group were treated with conventional therapy. Patients in the observation group were given antiviral therapy of entecavir on the basis of the control group, and the changes of each index level after 12 weeks and 24 weeks of treatment were evaluated. Results: Compared with control group, the contents of all indexes in observation group at 12 weeks and 24 weeks after treatment were significantly better than those in control group (P <0.05). The negative conversion rate of HBe Ag treatment group was 32.56% Which was significantly higher than that of the control group (9.30%, P <0.05). Conclusion: The efficacy of entecavir in the treatment of patients with hepatocellular carcinoma associated with hepatitis B can effectively improve its prognosis.